Melanie Mediavilla-Varela
Overview
Explore the profile of Melanie Mediavilla-Varela including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1047
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tebbi C, Sahakian E, Shah B, Yan J, Mediavilla-Varela M, Patel S
Biomedicines
. 2025 Feb;
13(2).
PMID: 40002901
Several etiologic factors for the development of acute leukemias have been suggested; however, none is applicable to all cases. We isolated a certain mycovirus-containing (MCAF) from the home of a...
2.
Gamal W, Goedhart N, Simon-Molas H, Mediavilla-Varela M, Uriepero-Palma A, Peters F, et al.
Blood Adv
. 2025 Feb;
PMID: 39938006
An unmet clinical need in chronic lymphocytic leukemia (CLL) is emerging due to the rapidly expanding group of patients with double refractory (BTK- and Bcl2-inhibitor) disease. So far, autologous T-cell-based...
3.
Tebbi C, Yan J, Sahakian E, Mediavilla-Varela M, Pinilla-Ibarz J, Patel S, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39408690
Transcription factors control genes to maintain normal hemopoiesis, and dysregulation of some factors can lead to acute lymphoblastic leukemia (ALL). Mycoviruses are known to alter the genetics of their fungal...
4.
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia
Gamal W, Mediavilla-Varela M, Uriepero-Palma A, Pinilla-Ibarz J, Sahakian E
Int J Mol Sci
. 2024 Jun;
25(12).
PMID: 38928031
Although preclinical investigations have shown notable efficacy in solid tumor models utilizing in vitro-differentiated Th17 cells for adoptive cell therapy (ACT), the potential benefits of this strategy in enhancing ACT...
5.
Maharaj K, Powers J, Mediavilla-Varela M, Achille A, Gamal W, Quayle S, et al.
Front Immunol
. 2020 Dec;
11:590072.
PMID: 33329575
Development of chronic lymphocytic leukemia (CLL) is associated with severe immune dysfunction. T-cell exhaustion, immune checkpoint upregulation, and increase of regulatory T cells contribute to an immunosuppressive tumor microenvironment. As...
6.
Maharaj K, Powers J, Achille A, Mediavilla-Varela M, Gamal W, Burger K, et al.
Blood Adv
. 2020 Jul;
4(13):3072-3084.
PMID: 32634240
The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and progression-free survival in clinical trials of B-cell malignancies, such as chronic lymphocytic...
7.
Gray J, Chiappori A, Williams C, Tanvetyanon T, Haura E, Creelan B, et al.
Cancer Immunol Immunother
. 2018 Sep;
67(12):1853-1862.
PMID: 30209589
The GM.CD40L vaccine, which recruits and activates dendritic cells, migrates to lymph nodes, activating T cells and leading to systemic tumor cell killing. When combined with the CCL21 chemokine, which...
8.
Mediavilla-Varela M, Castro J, Chiappori A, Noyes D, Hernandez D, Allard B, et al.
Neoplasia
. 2017 Jun;
19(7):530-536.
PMID: 28582704
Background: Therapeutic strategies targeting immune checkpoint proteins have led to significant responses in patients with various tumor types. The success of these studies has led to the development of various...
9.
Mediavilla-Varela M, Boateng K, Noyes D, Antonia S
BMC Cancer
. 2016 Mar;
16:176.
PMID: 26935219
Background: Anti-fibrotic drugs such as pirfenidone have been developed for the treatment of idiopathic pulmonary fibrosis. Because activated fibroblasts in inflammatory conditions have similar characteristics as cancer-associated fibroblasts (CAFs) and...
10.
Basu A, Cajigas-Du Ross C, Rios-Colon L, Mediavilla-Varela M, Daniels-Wells T, Leoh L, et al.
PLoS One
. 2016 Jan;
11(1):e0146549.
PMID: 26771192
Prostate cancer (PCa) mortality is driven by highly aggressive tumors characterized by metastasis and resistance to therapy, and this aggressiveness is mediated by numerous factors, including activation of stress survival...